The acquisition of $2.4 million in non-dilutive capital is a positive development for Citius Pharmaceuticals. It strengthens the company's financial position by providing additional capital that does not dilute existing shareholders' equity. This move is likely to be viewed positively by investors, as it demonstrates the company's ability to secure funding while preserving shareholder value. The involvement of the New Jersey Economic Development Program also adds a layer of credibility and support to the company's financial strategy.